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TB Elimination
Interferon-Gamma Release Assays 
(IGRAs) – Blood Tests for TB Infection
What are they?
Interferon-Gamma Release Assays (IGRAs) are 
whole-blood tests that can aid in diagnosing 
Mycobacterium tuberculosis infection. They do not 
help differentiate latent tuberculosis infection (LT BI) 
from tuberculosis disease. Two IGRAs that have  
been approved by the U.S. Food and Drug 
Administration (FDA) are commercially available  
in the U.S. They are:
 • QuantiFERON® – TB Gold In-Tube test  (QFT–GIT);
 • SPOT® TB test (T–Spot)
How do they work?
IGRAs measure a person’s immune reactivity  
to M. tuberculosis.  White blood cells from most 
persons that have been infected with M. tuberculosis 
will release interferon-gamma (IFN-g) when mixed 
with antigens (substances that can produce an 
immune response) derived from M. tuberculosis.  
To conduct the tests, fresh blood samples are mixed 
with antigens and controls. The antigens, testing 
methods, and interpretation criteria for IGRAs differ 
(see Table 1). 
What are the advantages of IGRAs?
 • Requires a single patient visit to conduct  
the test. 
 • Results can be available within 24 hours. 
 • Does not boost responses measured by 
subsequent tests.
 • Prior BCG (bacille Calmette-Guérin) 
vaccination does not cause a false-positive 
IGRA test result. 
What are the disadvantages and 
limitations of IGRAs?
 • Blood samples must be processed within 
8-30 hours after collection while white blood 
cells are still viable. 
 • Errors in collecting or transporting blood 
specimens or in running and interpreting the 
assay can decrease the accuracy of IGRAs. 
 • Limited data on the use of IGRAs to predict 
who will progress to TB disease in the future. 
Table1: Differences in Currently Available IGRAs
QFT–GIT T–Spot
Initial Process Process whole blood within 16 hours Process peripheral blood mononuclear 
cells (PBMCs) within 8 hours, or if T-Cell 
Xtend® is used, within 30 hours.
M. tuberculosis Antigen Single mixture of synthetic peptides 
representing ESAT-6, CFP-10 and TB7.7
Separate mixtures of synthetic peptides 
representing ESAT–6 and CFP-10
Measurement IFN-g concentration Number of IFN-g producing cells (spots)
Possible Results Positive, negative, indeterminate Positive, negative, indeterminate, 
borderline
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Limited data on the use of IGRAs for:
 » Children younger than 5 years of age; 
 » Persons recently exposed to M. tuberculosis;
 » Immunocompromised persons; and 
 » Serial testing. 
 • Tests may be expensive.
What are the steps in administering  
an IGRA test?
Confirm arrangements for testing in a qualified 
laboratory, and arrange for delivery of the 
blood sample to the laboratory in the time the 
laboratory specifies to ensure testing of samples 
with viable blood cells. 
 • Draw a blood sample from the patient 
according to the test manufacturer’s 
instructions. 
 • Schedule a follow-up appointment for the 
patient to receive test results.
 • Based on test results, provide follow-up 
evaluation and treatment as needed.
How do you interpret IGRA test 
results?
IGRA interpretations are based on the amount 
of IFN-g that is released or on the number 
of cells that release IFN-g. Both the standard 
qualitative test interpretation (positive, 
negative, or indeterminate) and the quantitative 
assay measurements (Nil, TB, and Mitogen 
concentrations or spot counts) should be 
reported.  
As with the tuberculin skin tests (TSTs), IGRAs 
should be used as an aid in diagnosing infection 
with M. tuberculosis. A positive test result suggests 
that M. tuberculosis infection is likely; a negative 
result suggests that infection is unlikely. An 
indeterminate result indicates an uncertain 
likelihood of M. tuberculosis infection. A borderline 
test result (T-Spot only) also indicates an uncertain 
likelihood of M. tuberculosis infection.
A diagnosis of LTBI requires that TB disease be 
excluded by medical evaluation. This should 
include checking for signs and symptoms 
suggestive of TB disease, a chest radiograph, and, 
when indicated, examination of sputum or other 
clinical samples for the presence of M. tuberculosis. 
Decisions about a diagnosis of M. tuberculosis 
infection should also include epidemiological and 
historical information. 
Recommendations on when to use 
IGRA tests
 • IGRAs can be used in place of (but not in 
addition to) TST in all situations in which CDC 
recommends TST as an aid in diagnosing 
M. tuberculosis infection, with preferences 
and special considerations noted below. 
This includes contact investigations, testing 
during pregnancy, and screening of health 
care workers and others undergoing serial 
evaluation for M. tuberculosis infection. 
Despite the indication of a preference, use of 
the alternative test (FDA-approved IGRA or 
TST) is acceptable medical and public health 
practice. Caution in interpretation should 
be used when testing certain populations 
because of limited data on the use of 
IGRAs (see Updated Guidelines for Using 
Interferon Gamma Release Assays to Detect 
Mycobacterium tuberculosis Infection, United 
States). 
 • Populations in which IGRAs are preferred for 
testing:
 » Persons who have received BCG (either as a 
vaccine or for cancer therapy); and 
 » Persons from groups that historically have 
poor rates of return for TST reading.
 • TST is preferred over IGRAs for testing children 
less than 5 years of age.
 • As with TST, IGRAs generally should not be 
used for testing persons who have a low risk 
of infection and a low risk of disease due to   
M. tuberculosis.
 • Each institution and TB control program 
should evaluate the availability and benefits 
of IGRAs in prioritizing their use.
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 • Routine testing with both TST and IGRA is 
not recommended. However, results from 
both tests might be useful in the following 
situations:
 » When the initial test is negative and:
 – The risk for infection, the risk for 
progression to disease, and the risk for a 
poor outcome are high (e.g., HIV infected 
persons or children under 5 years of 
age who are exposed to a person with 
infectious TB). 
 – There is clinical suspicion for TB 
disease (e.g., signs, symptoms, and/or 
radiographic evidence suggestive of   
TB disease) and confirmation of   
M. tuberculosis infection is desired. 
 – Taking a positive result from a second 
test as evidence of infection increases 
detection sensitivity.  
 » When the initial test is positive and:
 – Additional evidence of infection is 
required to encourage acceptance and 
adherence (e.g., foreign-born healthcare 
workers who believe their positive TST 
is due to BCG). A positive IGRA might 
prompt greater acceptance of treatment 
for LTBI as compared with a positive TST 
alone.
 – The person has a low risk of both 
infection and progression from infection 
to TB disease. Requiring a positive result 
from the second test as evidence of 
infection increases the likelihood that 
the test reflects infection. An alternative 
is to assume, without additional testing, 
that the initial result is a false positive or 
that the risk for disease does not warrant 
additional evaluation or treatment, 
regardless of test results.
 » In addition, repeating an IGRA or 
performing a TST might be useful when 
the initial IGRA result is indeterminate, 
borderline, or invalid and a reason for 
testing persists.
Multiple negative results from any combination 
of these tests cannot exclude M. tuberculosis 
infection. Steps should be taken to minimize 
unnecessary and misleading testing of persons 
at low risk. 
Selection of the most suitable test or 
combination of tests for detection of  
M. tuberculosis infection should be based on 
the reasons and the context for testing, test 
availability, and overall cost of testing.  
Can IGRAs Be Given To Persons 
Receiving Vaccinations?
As with TST, live virus vaccines might affect 
IGRA test results. However, the effect of live 
virus vaccination on IGRAs has not been 
studied. Until additional information is 
available, IGRA testing in the context of live 
virus vaccine administration should be done as 
follows:
 • Either on the same day as vaccination with 
live-virus vaccine or 4-6 weeks after the 
administration of the live-virus vaccine
 • At least one month after smallpox 
vaccination
Additional Information
Centers for Disease Control and Prevention. 
Updated Guidelines for Using Interferon 
Gamma Release Assays to Detect 
Mycobacterium tuberculosis Infection, United 
States. (PDF) MMWR 2010; 59 (No.RR-5). http://
www.cdc.gov/mmwr/preview/mmwrhtml/
rr5905a1.htm?s_cid=rr5905a1_e
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